Skip to main content
Eptifibatide peptide vial

Eptifibatide

FDA approved

Eptifibatide (Integrilin) is a cyclic heptapeptide antiplatelet drug approved by the FDA in 1998 for acute coronary syndrome and during coronary stenting. It is derived from a protein in rattlesnake venom.

At a glance

Where it acts
Heart & blood
Regulatory status
FDA approvedApproved by the U.S. FDA for at least one medical use.

Mechanism of Action

Eptifibatide blocks the glycoprotein IIb/IIIa receptor on platelets, the final common pathway of platelet clumping. Fibrinogen can no longer bridge platelets together, which prevents clots in coronary arteries.

Typical Dosage (Research)

Prescription-only medicine. Dosing is set by a physician according to the FDA-approved label and the condition being treated.

Side Effects & Risks

Bleeding (the most common) and low blood pressure.

Serious bleeding and low platelet counts (thrombocytopenia). Dose adjustment is needed in kidney impairment.

Who Uses Eptifibatide

Adults with acute coronary syndrome or undergoing PCI, in hospital settings.